Our findings demonstrate that while sustained Rac1 signaling (due to HER2 overexpression) may be a potent driver of transformation in human breast cancer, HACE1 is capable of tempering its downstream signaling ability. This evidence concerns the gene RAC1 and breast carcinoma.